Insights
Hong Kong biotech enters its second act with a licensing supercycle
New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.
Insights
New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.